Gerresheimer stock faced continued pressure on May 20, 2026, following a rating change. Jefferies downgraded the pharmaceutical packaging manufacturer from Buy to Hold on May 19. The investment bank reduced its price target for the company from €34.10 to €26.80.
Analysts cited concerns regarding delayed financial results and persistent market overhangs. The downgrade specifically highlights execution risks associated with the Bormioli Pharma acquisition. Jefferies warned that realizing synergies may prove slower and more costly than initially projected.